Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy

Background: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in better immunogenicity and less side effects. We report on patient safety and immunology of the first...

Descrición completa

Detalles Bibliográficos

Principais autores:	Cyrill A. Rentsch, Piet Bosshard, Grégoire Mayor, Malte Rieken, Heike Püschel, Grégory Wirth, Richard Cathomas, Gerald P. Parzmair, Leander Grode, Bernd Eisele, Hitt Sharma, Manish Gupta, Sunil Gairola, Umesh Shaligram, Daniel Goldenberger, François Spertini, Régine Audran, Milica Enoiu, Simona Berardi, Stefanie Hayoz, Andreas Wicki
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2020-01-01
Series:	OncoImmunology
Assuntos:	nmibc (non-muscle-invasive bladder cancer) bcg-failure clinical trial gmo (genetically modified organism) listeriolysin
Acceso en liña:	http://dx.doi.org/10.1080/2162402X.2020.1748981
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!